Abstract:Human cytomegalovirus (HCMV) is a β-herpesvirus that poses severe disease risk for immunocompromised patients who experience primary infection or reactivation. Development and optimization of safe and effective anti-HCMV therapeutics is of urgent necessity for the prevention and treatment of HCMV-associated diseases in diverse populations. The use of neutralizing monoclonal antibodies (mAbs) to limit HCMV infection poses a promising therapeutic strategy, as anti-HCMV mAbs largely inhibit infection by targeting virion glycoprotein complexes. In contrast, the small-molecule compounds currently approved for patients (e.g., ganciclovir, letermovir, and maribavir) target later stages of the HCMV life cycle. Here, we present a broadly neutralizing human mAb, designated 1C10, elicited from a VelocImmune mouse immunized with infectious HCMV particles. Clone 1C10 neutralizes infection after virion binding to cells by targeting gH/gL envelope complexes and potently reduces infection of diverse HCMV strains in fibroblast, trophoblast, and epithelial cells. Antibody competition assays found that 1C10 recognizes a region of gH associated with broad neutralization and binds to soluble pentamer in the low nanomolar range. Importantly, 1C10 treatment significantly reduced virus proliferation in both fibroblast and epithelial cells. Further, the combination treatment of mAb 1C10 with ganciclovir reduced HCMV infection and proliferation in a synergistic manner. This work characterizes a neutralizing human mAb for potential use as a HCMV treatment, as well as a possible therapeutic strategy utilizing combination-based treatments targeting disparate steps of the viral life cycle. Collectively, the findings support an antibody-based therapy to effectively treat patients at risk for HCMV-associated diseases. Importance: Human cytomegalovirus is a herpesvirus that infects a large proportion of the population and can cause significant disease in diverse patient populations whose immune systems are suppressed or compromised. The development and optimization of safe anti-HCMV therapeutics, especially those that have viral targets and inhibition mechanisms different from current HCMV treatments, are of urgent necessity to better public health. Human monoclonal antibodies (mAbs) that prevent HCMV entry of cells were identified by immunizing transgenic mice and screened for broad and effective neutralization capability. Here, we describe one such mAb, which was found to target gH/gL envelope complexes and effectively limit HCMV infection and dissemination. Further, administration of the antibody in combination with the antiviral drug ganciclovir inhibited HCMV in a synergistic manner, highlighting this approach and the use of anti-HCMV mAbs more broadly, as a potential therapeutic strategy for the treatment of diverse patient populations.

A Novel Polyclonal Antibody Against Human Cytomegalovirus: General Characteristics and Potential Application in Diagnosis

Development of Two Potential Diagnostic Monoclonal Antibodies Against Human Cytomegalovirus Glycoprotein B

Recombinant Human IgG Antibodies Against Human Cytomegalovirus

Human Mannose‐binding Lectin Inhibits Human Cytomegalovirus Infection in Human Embryonic Pulmonary Fibroblast

Towards a Novel Vaccine Against Human Cytomegalovirus Based on a Chimeric Ad5F35 Adenovirus Vector Expressing the Immunodominant Antigenic Domain 1 Epitope.

Preclinical Evaluations of Peptide-Conjugate Vaccines Targeting the Antigenic Domain-2 of Glycoprotein B of Human Cytomegalovirus.

Neutralization of Diverse Human Cytomegalovirus Strains Conferred by Antibodies Targeting Viral Gh/gl/pul128-131 Pentameric Complex

Designing a novel multi‐epitope antigen for diagnosing human cytomegalovirus infection: An immunoinformatics approach

A broadly neutralizing human monoclonal antibody generated from transgenic mice immunized with HCMV particles limits virus infection and proliferation

Development of broadly neutralizing antibodies targeting the cytomegalovirus subdominant antigen gH

The Development of Chinese Specific Human Cytomegalovirus Polyepitope Recombinant Vaccine

Novel Potent Neutralizing Antibodies Revealed the Domain I of HCMV Glycoprotein B for Vaccine Design

Preparation of polyclonal antibody against human cytomegalovirus UL 146 gene product – α chemokine vCXC-1

Development and characterization of HCMV recombinant subunit vaccines based on T-cell epitopes

Evaluation of HCMV Vaccines in Rhesus Macaques by a Novel Micro-Neutralization Assay (113.4)

Production of Monoclonal Antibodies Against Phosphoprotein 65 from Human Cytomegalovirus.

Rapid and sensitive identification of glycoprotein h genotypes in clinical human cytomegalovirus samples.

Monitoring of human cytomegalovirus infection in bone marrow and liver transplant recipients by antigenaemia assay and enzyme-linked immunosorbent assay.

A neutralizing anti-gH/gL monoclonal antibody is protective in the guinea pig model of congenital CMV infection.

Restoration of viral epithelial tropism improves immunogenicity in rabbits and rhesus macaques for a whole virion vaccine of human cytomegalovirus.

DNA Vaccines Expressing Glycoprotein Complex II Antigens Gm and Gn Elicited Neutralizing Antibodies Against Multiple Human Cytomegalovirus (HCMV) Isolates.